Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1925 1
1959 1
1964 1
1965 2
1966 1
1969 1
1971 2
1972 1
1973 3
1974 1
1975 16
1976 8
1977 4
1978 12
1979 10
1980 14
1981 18
1982 19
1983 22
1984 27
1985 28
1986 25
1987 29
1988 32
1989 48
1990 40
1991 44
1992 44
1993 49
1994 58
1995 61
1996 72
1997 84
1998 87
1999 103
2000 101
2001 82
2002 80
2003 96
2004 123
2005 137
2006 113
2007 129
2008 145
2009 172
2010 161
2011 190
2012 180
2013 215
2014 234
2015 217
2016 184
2017 174
2018 209
2019 217
2020 217
2021 274
2022 208
2023 180
2024 62

Text availability

Article attribute

Article type

Publication date

Search Results

4,546 results

Results by year

Filters applied: . Clear all
Page 1
Acalabrutinib Versus Investigator's Choice in Relapsed/Refractory Chronic Lymphocytic Leukemia: Final ASCEND Trial Results.
Ghia P, Pluta A, Wach M, Lysak D, Šimkovič M, Kriachok I, Illés Á, de la Serna J, Dolan S, Campbell P, Musuraca G, Jacob A, Avery EJ, Lee JH, Usenko G, Wang MH, Yu T, Jurczak W. Ghia P, et al. Hemasphere. 2022 Nov 14;6(12):e801. doi: 10.1097/HS9.0000000000000801. eCollection 2022 Dec. Hemasphere. 2022. PMID: 36398134 Free PMC article.
ASCEND is the pivotal phase 3 study of acalabrutinib versus investigator's choice of idelalisib plus rituximab (IdR) or bendamustine plus rituximab (BR) in patients with relapsed/refractory (R/R) CLL. ...Patients with R/R CLL received oral acalabrutinib 100 mg twice daily …
ASCEND is the pivotal phase 3 study of acalabrutinib versus investigator's choice of idelalisib plus rituximab (IdR) or bendamustine …
Transcriptomics technologies.
Lowe R, Shirley N, Bleackley M, Dolan S, Shafee T. Lowe R, et al. PLoS Comput Biol. 2017 May 18;13(5):e1005457. doi: 10.1371/journal.pcbi.1005457. eCollection 2017 May. PLoS Comput Biol. 2017. PMID: 28545146 Free PMC article.
Transcriptomics technologies are the techniques used to study an organism's transcriptome, the sum of all of its RNA transcripts. The information content of an organism is recorded in the DNA of its genome and expressed through transcription. ...There are two key contempor …
Transcriptomics technologies are the techniques used to study an organism's transcriptome, the sum of all of its RNA transcripts. The …
A Pseudomonas aeruginosa small RNA regulates chronic and acute infection.
Cao P, Fleming D, Moustafa DA, Dolan SK, Szymanik KH, Redman WK, Ramos A, Diggle FL, Sullivan CS, Goldberg JB, Rumbaugh KP, Whiteley M. Cao P, et al. Nature. 2023 Jun;618(7964):358-364. doi: 10.1038/s41586-023-06111-7. Epub 2023 May 24. Nature. 2023. PMID: 37225987 Free PMC article.
Toward Understanding Death.
Dolan SB, Mahon BE, Dowell SF, Zaidi A. Dolan SB, et al. Clin Infect Dis. 2021 Dec 15;73(Suppl_5):S341-S342. doi: 10.1093/cid/ciab809. Clin Infect Dis. 2021. PMID: 34910167 Free PMC article.
Women's health update: A literature review impacting primary care.
Dolan BM, Merriam S, Prifti CA, Walsh JM. Dolan BM, et al. Cleve Clin J Med. 2022 Jul 1;89(7):373-381. doi: 10.3949/ccjm.89a.21123. Cleve Clin J Med. 2022. PMID: 35777837 Free article. Review.
The authors review studies on key issues in women's health with potential impact on internal medicine practice. The reviewed articles discuss cardiovascular disease risks, bone health, breast cancer genetics, cervical cancer prevention, depression in the peripartum period, …
The authors review studies on key issues in women's health with potential impact on internal medicine practice. The reviewed articles …
Effective presentation skills.
Dolan R. Dolan R. FEMS Microbiol Lett. 2017 Dec 29;364(24). doi: 10.1093/femsle/fnx235. FEMS Microbiol Lett. 2017. PMID: 29106534
Most PhD's will have a presentation component during the interview process, as well as presenting their work at conferences. ...
Most PhD's will have a presentation component during the interview process, as well as presenting their work at conferences. ...
On aggregating QALYs: a comment on Dolan.
Johannesson M. Johannesson M. J Health Econ. 1999 Jun;18(3):381-6. doi: 10.1016/s0167-6296(98)00052-6. J Health Econ. 1999. PMID: 10537901
Dolan [Dolan, P., 1998, The measurement of individual utility and social welfare. Journal of Health Economics, Vol. 17, pp. 39-52] in a recent paper suggested an empirical method for estimating the shape of the social welfare function. Using a simple theoretical mod …
Dolan [Dolan, P., 1998, The measurement of individual utility and social welfare. Journal of Health Economics, Vol. 17, pp. 39 …
Interprofessional socialization: a concept analysis.
Dolan S, Nowell L. Dolan S, et al. J Interprof Care. 2023 Sep 13:1-12. doi: 10.1080/13561820.2023.2253845. Online ahead of print. J Interprof Care. 2023. PMID: 37705124 Review.
Interprofessional socialization is an iterative process in which members from different professions come together to learn about and value each other's perspectives and contributions, while dispelling misconceptions and prejudices, continuously working toward formation of …
Interprofessional socialization is an iterative process in which members from different professions come together to learn about and value e …
On Saville-Kent's "a Manual of the infusoria".
Dolan JR. Dolan JR. Protist. 2024 Feb;175(1):126008. doi: 10.1016/j.protis.2023.126008. Epub 2023 Dec 23. Protist. 2024. PMID: 38219636 No abstract available.
4,546 results